Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673867 · ClinicalTrials.gov registry record · Phase 3
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 582
- Enrollment target
NCT01673867 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 582 participants.
The verdict
NCT01673867, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 582 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy
Interventions
- DRUG Docetaxel
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 2012-11-02 |
| Est. Completion | 2021-12-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673867
The ClinicalTrials.gov registry entry for NCT01673867 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 582 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01673867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673867 about?
NCT01673867 is a clinical study titled "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC". The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy
What is the current status of trial NCT01673867?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 582 participants. The study started on 2012-11-02. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT01673867?
The interventions under investigation include: Docetaxel (DRUG), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01673867?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.